Supriya Lifescience Faces ₹603.8 Crore Tax Demand

1 min read     Updated on 01 Jul 2025, 05:11 PM
scanxBy ScanX News Team
whatsapptwittershare
Overview

Supriya Lifescience, a pharmaceutical company, has received a tax demand notice of ₹603.80 crore from the Tax Department. The company has not provided specific details about the nature of the tax assessment or the period it covers. This substantial demand could potentially impact the company's finances and operations. Investors are awaiting further information and the company's response to this development.

12915722

*this image is generated using AI for illustrative purposes only.

Supriya Lifescience , a prominent player in the pharmaceutical sector, has recently come under the scrutiny of the Tax Department. The company has received a substantial tax demand notice, raising concerns among investors and industry watchers alike.

Tax Department Issues Notice

Supriya Lifescience has disclosed that it has received a notice from the Tax Department, demanding a significant sum of ₹603.80 crore. This development has caught the attention of the financial community, given the magnitude of the amount involved.

Limited Information Available

As of now, details surrounding this tax demand remain scarce. The company has not provided specific information regarding the nature of the tax assessment or the time period it covers. This lack of clarity leaves several questions unanswered about the potential impact on the company's financials and operations.

Implications for Supriya Lifescience

The tax demand of ₹603.80 crore is a substantial figure that could have significant implications for Supriya Lifescience. Depending on the company's current financial position and the outcome of any potential appeals or negotiations with the Tax Department, this demand could affect the company's liquidity, profitability, and future growth plans.

Next Steps

Investors and stakeholders will be keenly watching for further announcements from Supriya Lifescience regarding this matter. The company is expected to provide more details about the tax demand, including any plans to contest the notice or engage in discussions with the Tax Department.

As this situation unfolds, it will be crucial for Supriya Lifescience to maintain transparent communication with its shareholders and the market at large. The company's response to this tax demand and its ability to navigate through this challenge will be closely monitored by the financial community in the coming days and weeks.

Historical Stock Returns for Supriya Lifescience

1 Day5 Days1 Month6 Months1 Year5 Years
+2.18%+6.22%+1.11%-4.23%+82.04%+85.37%
Supriya Lifescience
View in Depthredirect
like16
dislike

Supriya Lifescience Unveils Ambitious Growth Strategy, Targets ₹1,000 Crore Revenue by FY27

1 min read     Updated on 29 May 2025, 09:03 AM
scanxBy ScanX News Team
whatsapptwittershare
Overview

Supriya Lifescience announced robust growth plans during a recent conference call. The company's formulation facility is expected to generate ₹450-500 crore in revenue. They maintained a 20% annual revenue growth guidance with EBITDA margins of 33-35%. A mid-term goal of ₹1,000 crore revenue by FY2027 was set. The company anticipates stronger volume growth over the next two years, driven by full capacity utilization of Module E by FY27 and launch of new products with significant global volume potential.

10035187

*this image is generated using AI for illustrative purposes only.

Supriya Lifescience , a prominent player in the pharmaceutical industry, has outlined its robust growth plans and financial targets during a recent conference call, signaling a bullish outlook for the company's future.

Formulation Facility to Drive Revenue Growth

The company revealed that its formulation facility has the potential to generate substantial revenue, estimating between ₹450.00-500.00 crore. This facility is expected to be capitalized by the second quarter or early third quarter, marking a significant milestone in Supriya Lifescience's expansion strategy.

Strong Financial Guidance

Reaffirming its commitment to growth, Supriya Lifescience has maintained its guidance of 20% annual revenue growth. The company expects to sustain its EBITDA margins within the range of 33.00% to 35.00%, demonstrating confidence in its operational efficiency and profitability.

Mid-Term Revenue Target

In a bold move, Supriya Lifescience has set an ambitious mid-term goal to achieve ₹1,000.00 crore in revenue by the financial year 2027. This target underscores the company's aggressive growth strategy and its optimism about market opportunities.

Volume Growth and Capacity Utilization

The company anticipates stronger volume growth over the next two years, driven by two key factors:

  1. Full capacity utilization of Module E by FY27
  2. Launch of new products with significant global volume potential

Outlook

Supriya Lifescience's strategic plans and financial targets reflect its confidence in its business model and market position. The company's focus on expanding its formulation facility, coupled with the introduction of new products, positions it well for sustained growth in the coming years.

As the pharmaceutical industry continues to evolve, Supriya Lifescience's clear roadmap and ambitious targets demonstrate its commitment to creating value for stakeholders while capitalizing on emerging opportunities in the global market.

Historical Stock Returns for Supriya Lifescience

1 Day5 Days1 Month6 Months1 Year5 Years
+2.18%+6.22%+1.11%-4.23%+82.04%+85.37%
Supriya Lifescience
View in Depthredirect
like18
dislike
More News on Supriya Lifescience
Explore Other Articles
Hindware Expands Production Capacity with New Rs 170 Crore Plant in Roorkee 3 hours ago
CEIGALL India Secures Massive ₹1,199 Crore Order from NHAI 3 hours ago
V-Mart Retail: Q1 Revenue Up 12.6%, Expands Store Network 5 hours ago
724.50
+15.45
(+2.18%)